2021
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 5023-5023. DOI: 10.1200/jco.2021.39.15_suppl.5023.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPositive predictive valuePhase 3 studyPET/CTProstate cancerPrimary endpointPSA responseF-DCFPyL PET/CT scansF-fluciclovine PET/CTProspective phase 3 studyCorrelative imaging findingsRecurrent prostate cancerPET/CT accuracyConventional imaging modalitiesClinical trial informationDefinitive therapyLocal therapyBaseline imagingMetastatic lesionsImaging findingsAnatomic lesionsLower PSAF-DCFPyLTreatment responseCT scanA prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: e17003-e17003. DOI: 10.1200/jco.2021.39.15_suppl.e17003.Peer-Reviewed Original ResearchF-DCFPyL PET/CTProstate cancerF-DCFPyLPositron emission tomographyConventional imagingM1 diseaseBone scintigraphyStaging of PCaHigh-risk prostate cancerWhole-body bone scintigraphyM1 stage diseasePhase 2/3 studyCT detection rateMajority of patientsPET/CTLocoregional diseaseRadiologic evidenceStage diseaseLocal recurrenceMetastatic diseasePelvic LNSingle doseTNM stagingImaging reviewLesion countsA prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: 32-32. DOI: 10.1200/jco.2021.39.6_suppl.32.Peer-Reviewed Original ResearchF-DCFPyL PET/CTProstate cancerF-DCFPyLPositron emission tomographyConventional imagingM1 diseaseBone scintigraphyPhase II/III studyStaging of PCaHigh-risk prostate cancerWhole-body bone scintigraphyM1 stage diseaseCT detection rateMajority of patientsPET/CTLocoregional diseaseRadiologic evidenceIII studyStage diseaseLocal recurrenceMetastatic diseasePelvic LNSingle doseTNM stagingImaging reviewPSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 33-33. DOI: 10.1200/jco.2021.39.6_suppl.33.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPositive predictive valuePET/CTProstate cancerPrimary endpointPSA responseF-DCFPyL PET/CT scansF-fluciclovine PET/CTProspective phase 3 studyBiochemically recurrent prostate cancerCorrelative imaging findingsPhase 3 studyPhase III studyRecurrent prostate cancerPET/CT accuracyConventional imaging modalitiesDefinitive therapyIII studyLocal therapyMetastatic lesionsBaseline imagingImaging findingsAnatomic lesionsLower PSAF-DCFPyL
2020
LBA02-12 A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL
Gorin* M, Siegel B, Rowe S, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Carroll P. LBA02-12 A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000958.012.Peer-Reviewed Original ResearchA prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.
Pouliot F, Carroll P, Probst S, Pienta K, Rowe S, Saperstein L, Siegel B, Patnaik A, Preston M, Alva A, Gorin M, Morris M. A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT. Journal Of Clinical Oncology 2020, 38: 9-9. DOI: 10.1200/jco.2020.38.6_suppl.9.Peer-Reviewed Original ResearchHigh-risk prostate cancerF-DCFPyL PET/CTPET/CTRisk prostate cancerF-DCFPyLProstate cancerPositron emission tomographyM1 diseaseInitial stagingMetastatic lesionsPET/CT detection rateStandard cross-sectional imagingMetastasis detection rateDistant metastatic lesionsCT detection rateMetastatic prostate cancerCross-sectional imagingCurrent imaging modalitiesPositive predictive valueDetection rateEvaluable ptsPelvic LNsN1 diseaseMetastatic diseasePelvic LN
2019
Diagnostic performance of 18 F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18 F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).
Morris M, Durack J, Alva A, Vargas H, Piert M, Pachynski R, Pouliot F, Beauregard J, Preston M, Choudhury A, Saperstein L, Carroll P, Rowe S, Pienta K, Lin T, Wong V, Nichols M, Jensen J, Siegel B. Diagnostic performance of 18 F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18 F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC). Journal Of Clinical Oncology 2019, 37: 5012-5012. DOI: 10.1200/jco.2019.37.15_suppl.5012.Peer-Reviewed Original ResearchF-DCFPyL PET/CTMetastatic prostate cancerF-DCFPyL PET/CT scansPET/CTPositive predictive valuePET/CT scansProstate cancerF-DCFPyLPET imaging agentMulticenter studyCT scanNovel PET imaging agentHigh-risk prostate cancerDrug-related AEsDiagnostic performanceHigh positive predictive valueSoft tissue metastasesProstate-specific membrane antigenSite of diseaseImage-guided biopsyImaging agentDistant diseaseTissue metastasesCohort B.Patient managementA phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).
Morris M, Pouliot F, Saperstein L, Rowe S, Gorin M, Josephson D, Wong J, Carroll P, Lin T, Stambler N, Wong V, Jensen J, Siegel B. A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). Journal Of Clinical Oncology 2019, 37: tps5093-tps5093. DOI: 10.1200/jco.2019.37.15_suppl.tps5093.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPET/CTRecurrent prostate cancerMetastatic prostate cancerProstate cancerF-DCFPyLPositron emission tomographyClinical impactDiagnostic performancePET/CT resultsEquivocal conventional imagingOpen-label studyWhole-body PET/CTProstate-specific membrane antigenYears of ageUnmet diagnostic needsEligible patientsF-fluciclovineDefinitive therapyBaseline PSAMulticenter studyDetection rateProstate adenocarcinomaPatient managementC-choline
2018
A prospective phase 2/3 multicenter study of 18 F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).
Morris M, Carroll P, Probst S, Pouliot F, Saperstein L, Siegel B, Alva A, Preston M, Patnaik A, Gorin M, Durack J, Nichols M, Lin T, Strack T, DiPippo V, Jensen J, Mahmood S, Wong V, Pienta K. A prospective phase 2/3 multicenter study of 18 F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY). Journal Of Clinical Oncology 2018, 36: tps5092-tps5092. DOI: 10.1200/jco.2018.36.15_suppl.tps5092.Peer-Reviewed Original Research